Genomic Landscape of Waldenström Macroglobulinemia
Overview
Oncology
Affiliations
Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM). Common mutations include MYD88 (95%-97%), as well as CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%), which are typically found in MYD88-mutated patients. The genomic findings provide important insights into the pathogenesis, prognostication, and treatment outcome in WM. We discuss the genomic landscape of WM, and the impact of underlying genomics on disease presentation, transcriptional changes, treatment outcome, and overall survival impact.
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.
Venturutti L, Rivas M, Pelzer B, Flumann R, Hansen J, Karagiannidis I Cancer Discov. 2022; 13(1):216-243.
PMID: 36264161 PMC: 9839622. DOI: 10.1158/2159-8290.CD-22-0561.
From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.
Visentin A, Pravato S, Castellani F, Campagnolo M, Angotzi F, Cavarretta C Cancers (Basel). 2022; 14(6).
PMID: 35326711 PMC: 8946535. DOI: 10.3390/cancers14061562.
Boiza-Sanchez M, Manso R, Balague O, Chamizo C, Askari E, Salgado R PLoS One. 2020; 15(11):e0241634.
PMID: 33180881 PMC: 7661053. DOI: 10.1371/journal.pone.0241634.